Paper Review Records
全部论文审稿周期
11 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
50
天
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial
作者
Yun Fan; Yanqiu Zhao; Dingzhi Huang; Jun Zhao; Tai Qin; Wanyu He; Chenqi Chen; Pu Sun; Kirsha Naicker; Yong Song展开收起
作者单位
Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China; Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department I of Thoracic Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., Beijing, China; Statistics, BeOne Medicines, Ltd., New York, New York; Clinical Biomarkers, BeOne Medicines, Ltd., Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., London, United Kingdom; Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China展开收起
245
天
Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC
作者
Santiago Ponce; Miguel Ruiz-Torres; Alejandro Falcón; Gregory M. Cote; Reyes Bernabé; Jessica J. Lin; Juan Manuel Coya; Marta Jiménez-Muñoz; Pablo Fernández-Puyuelo; Amparo Sánchez; Jon Zugazagoitia; Alvaro Ucero; Javier Baena; Helena Bote de Cabo; Mercedes Herrera; Javier Torres-Jiménez; Maria Zurera; Carmen Kahatt; Jose Antonio Lopez-Vilariño; Sara Martinez; Mariano Siguero; Marcos Malumbres; Irene Ferrer; Luis Paz-Ares展开收起
作者单位
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO)-Hospital 12 de Octubre (H12O) Lung Cancer Clinical Cancer Research Unit, Instituto de Investigación Biomédica i+12 and CNIO, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Massachusetts General Hospital, Boston, Massachusetts; Physiology and Medicine Departments, Universidad Complutense, Madrid, Spain; Oncology Clinical Development, Pharma Mar, Colmenar Viejo, Madrid, Spain; Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain展开收起
99
天
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
作者
Oliver Illini; Anna-Carina Hund; Hans-Georg Kopp; Mor Moskovitz; Giannis Mountzios; Wolfgang M. Brueckl; Martin Früh; Marie-Elisabeth Leßmann; Petros Christopoulos; Albrecht Stenzinger; Michael Thomas; Roni Gillis; Nir Peled; Fabian Acker; Alfredo Addeo; Andriani Charpidou; Christian Grohé; Horst-Dieter Hummel; Laetitia Mauti; Sacha I. Rothschild; Sabine Schmid; Christian Schumann; Damien Urban; Robert Wurm; Simon Ekman; Marcus Skribek; Franziska Glanemann; Marcel Wiesweg; Christoph Jakob Ackermann; Sofia Agelaki; Petra Hoffknecht; Marko Jakopović; Jens Kern; David König; Katharina Kostenzer; Cornelia Kropf-Sanchen; Eckart Laack; David Lang; Laurenz Nagl; Georg Pall; Martin Reck; Waleed Kian; Anna T. Allemann; Jürgen Alt; David Araújo; Hanibal Bohnenberger; Alexandros Bokas; Hannah Fabikan; Krainer-Jacobs Julie; Christoph Weinlinger; Adrianus Johannes de Langen; Evangelos Georgios Fergadis; Rieke Fischer; Elena Fountzilas; Patrizia Froesch; Nikolaj Frost; Frank Griesinger; Franziska Jordan; Charisios Karanikiotis; Barbara Kiesewetter; Ippokratis Korantzis; Andrea Lopes Machado; Panagiota Economopoulou; Arnold Pilz; Patrick Reimann; Achim Rittmeyer; Akram Saad; Konstantinos Samitas; Karsten Schulmann; Riyaz Shah; Jan Alexander Stratmann; Hossein Taghizadeh; Kai Tammoscheit; Amanda Tufman; Jan-Phillip Weber; Ewald Wöll; Arschang Valipour; Tobias R. Overbeck; Maximilian J. Hochmair展开收起
作者单位
Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria; Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany; National Network Genomic Medicine, Cologne, Germany; Department of Hematology, Oncology, and Palliative Care, Robert Bosch Center for Tumor Diseases, Stuttgart, Germany; Davidoff Cancer Center, Beilinson MC, Petah Tikva, Israel; 4th Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece; Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany; Department of Oncology and Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland; Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Department of Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Institute for Pathology, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany; Department of Translational Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Hematology and Oncology, Frankfurt, Germany; Oncology Department, University Hospital Geneva, Geneva, Switzerland; Oncology Unit, 3rd Department of Internal Medicine and Laboratory Medical School, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece; Klinik für Pneumologie, Evangelische Lungenklinik, Berlin, Germany; Translational Oncology/Early Clinical Trial Unit (ECTU), Bavarian Cancer Research Center, National Center for Tumor Diseases, Comprehensive Cancer Center Mainfranken and University Hospital Würzburg, Würzburg, Germany; Medizinische Onkologie, Kantonsspital Winterthur, Winterthur, Switzerland; Department of Internal Medicine, Center of Oncology & Hematology, Cantonal Hospital Baden, Baden, Switzerland and University of Basel, Medical Faculty, Basel, Switzerland; Respiratory Critical Care, Allgäu Clinics, Kempten and Immenstadt, Kempten, Germany; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Thoracic Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Oncology and Haematologie Thun-Spiez-Berner-Oberland, Thun, Switzerland; Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece; Department of Thoracic Oncology, Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg, Georgsmarienhütte, Germany; Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; KWM-Standort Missioklinik, Würzburg, Germany; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Department of Pneumology, LKH Hochzirl-Natters, Tirol Kliniken, Natters, Austria; Department II for Internal Medicine, University Hospital of Ulm, Ulm, Germany; Hemato-Oncology Hamburg, Hamburg, Germany; Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria; Department of Internal Medicine V - Haematology and Oncology, Tirol Kliniken, Medical University Innsbruck, Innsbruck, Austria; Department of Internal Medicine 2, Kardinal Schwarzenberg Hospital, Schwarzach im Pongau, Austria; Department of Thoracic Oncology, LungenClinic, Grosshansdorf, Germany; Airway Research Center North, German Center for Lung Research, Giessen, Germany; Oncology Department, Samson Assuta Ashdod University Hospital, Ashdod, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Department of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Spitalstrasse, Luzern, Switzerland; Department of Hematology and Medical Oncology, University Medical Center Mainz, Mainz, Germany; Department of Pulmonology, Unidade Local de Saúde São João, Porto, Portugal; Faculty of Medicine, Universidade do Porto, Porto, Portugal; Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; 1st Department of Clinical Oncology, Theagenio Cancer Hospital of Thessaloniki, Thessaloniki, Greece; Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands; Medical Oncology Department, Metaxa Cancer Hospital, Piraeus, Greece; Department I of Internal Medicine, Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany; European University Cyprus, German Oncology Center, Nicosia, Cyprus; Department of Medical Oncology, St Luke's Clinic, Thessaloniki, Greece; Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Hematology and Medical Oncology, Pius-Hospital, Department of Internal Medicine-Oncology, University Medicine Oldenburg, Oldenburg, Germany; Department of Pneumology, University Hospital Salzburg, Salzburg, Austria; Department of Medical Oncology, Euromedica - Kianous Stavros Clinic, Thessaloniki, Greece; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria; St Luke’s Hospital, Panorama, Thessaloniki, Greece; Department of Pulmonary Oncology - ULS Santa Maria/Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Oncology Unit, Second Department of Internal Medicine, Attikon University Hospital, Athens, Greece; Department of Respiratory and Pulmonary Diseases, Clinic Penzing, Vienna Healthcare Group, Vienna, Austria; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria; Department of Haematology, Oncology, Gastroenterology and Infectiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Department of Thoracic Oncology, LKI Lungenfachklinik Immenhausen, Immenhausen, Germany; Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel; 7th Respiratory Department, Athens Chest Hospital “Sotiria,” Athens, Greece; Department of Pneumology, Division of Thoracic Oncology and Palliative Care, Lungenklinik Hemer, Hemer, Germany; GenesisCare Maidstone, Kings Hill, West Malling, United Kingdom; UKS Homburg, Homburg, Germany; Oncology, University Hospital St. Pölten, St. Pölten, Lower Austria, Austria; Karl Landsteiner Institute of Nephrology and Hematooncology, Lower Austria, Austria; Hessenklinik Stadtkrankenhaus Korbach, Korbach, Germany; Department of Internal Medicine V, Comprehensive Pneumology Center (CPC-M), Ludwig-Maximilians-Universität Munich, Germany; German Center for Lung Research (DZL), Bavarian Center for Cancer Research (BZKF), Germany; MVZ Oncology and Hematology, Sachsenring, Köln, Germany; Head of Department of Internal Medicine, Head of Laboratory Unit, Executive Medical Director, Krankenhaus St. Vinzenz, Zams, Austria展开收起
12
天
Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay
作者
Jamie Feng; Sameena Khan; Thomas K. Waddell; Kazuhiro Yasufuku; Zachary Coyne; Deirdre Kelly; Nicholas Meti; Najib Safieddine; Michael Ko; Andrew Pierre; Shaf Keshavjee; Elliot Wakeam; Laura Donahoe; Marcelo Cypel; Jonathan Yeung; Marc de Perrot; Negar Ahmadi; Sayf Gazala; Carmine Simone; David Parente; Mary R. Rabey; Jennifer H. Law; Janice J.N. Li; Alexandra Salvarrey; Lisa W. Le; Andrew Seto; Michael Cabanero; Ming-Sound Tsao; Christodoulos Pipinikas; Amber Chevalier; Scott V. Bratman; Natasha B. Leighl展开收起
作者单位
Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Division of Thoracic Surgery, University Health Network (UHN), Toronto, Ontario, Canada; Division of Thoracic Surgery, Michael Garron Hospital, Toronto, Ontario, Canada; Division of Thoracic Surgery, Unity Health Toronto, Toronto, Ontario, Canada; Department of Biostatistics, University Health Network, Toronto, Ontario, Canada; Division of Pathology and Cytogenetics, Laboratory Medicine Program, UHN, Toronto, Ontario, Canada; NeoGenomics Inc., Fort Myers, Florida; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada展开收起
79
天
Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening
作者
Anna Zanghì; Massimo Moro; Orazio Fortunato; Miriam Segale; Federica Sabia; Paola Suatoni; Roberta E. Ledda; Luigi Rolli; Alfonso Marchianò; Ugo Pastorino; Gabriella Sozzi; Mattia Boeri展开收起
作者单位
Unit of Epigenomics & Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Section of Radiology, Unit of Surgical Sciences, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天